NCT06689514View on ClinicalTrials.gov

Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Prostatic Hypertrophy, Benign

Interventions

DRUG

alpha receptor antagonist

Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)

DRUG

Low dose Tranilast

Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 100mg TID

DRUG

High dose Tranilast

Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 200mg TID

Trial Locations (1)

200086

Shanghai General Hospital, Shanghai

All Listed Sponsors

lead

Yifeng Jing

OTHER

NCT06689514 - Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia | Biotech Hunter | Biotech Hunter